ORI goes oncolytic

Oncolytic virus company Cold Genesys continues to draw East Asian investors on the back of its data in bladder cancer.

ORI Healthcare Fund L.P.'s Simone Song said the Hong Kong fund had been following Cold Genesys Inc. since 2015 and was impressed by the company's data. Song decided to invest in the Santa Ana, Calif., company’s recent $22 million series C after founder Alex Yeung was replaced as CEO with Arthur Kuan in 2017, who had been COO. ...